Literature DB >> 14613209

Nanocapillary liquid chromatography interfaced to tandem matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry: mapping the nuclear proteome of human fibroblasts.

Johan Malmström1, Kristoffer Larsen, Lars Malmström, Ellen Tufvesson, Ken Parker, Jason Marchese, Brian Williamson, Dale Patterson, Steve Martin, Peter Juhasz, Gunilla Westergren-Thorsson, György Marko-Varga.   

Abstract

Miniaturized liquid chromatography nanoseparation in combination with minigel fractionation of human primary cell nuclei is presented. We obtained high-sensitivity and high-throughput identification of expressed proteins by subcellular fractionation and nanocapillary liquid chromatography interfaced to both electrospray ionization (ESI)- and matrix-assisted laser desorption/ionisation (MALDI) tandem mass spectrometry. The reversed-phase nanocapillary eluents were applied directly onto the MALDI target plate as discrete crystal spots using in-line matrix infusion. When working with primary cells, only a limited amount of sample is available. To maximize the number of identified proteins from a restricted amount of sample, miniaturized sample preparation protocols and nanoflow separation is a necessity, especially when working with low-abundant proteins. From the same isolated nuclear sample, complementary separation of intact proteins by two-dimensional (2-D) gel electrophoresis was made. In total 594 gene products from the nuclear preparations were identified out of which 261 were unique. Several proteins involved in transcriptional events were identified such as TATA-binding protein, EBNA-co-activator, and interleukin enhancer binding proteins, indicating that sufficient proteomic depth is obtained to study transcriptional controlling events. Our results suggest that by sample prefractionation and downscaled nanoflow separation along with a combined mass spectrometry strategy, it is possible to identify a large number of nuclear proteins from human primary cells. These findings are of particular importance due to the disease link of these targets cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613209     DOI: 10.1002/elps.200305619

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  6 in total

1.  Analysis of protein-protein interaction surfaces using a combination of efficient lysine acetylation and nanoLC-MALDI-MS/MS applied to the E9:Im9 bacteriotoxin--immunity protein complex.

Authors:  Arjen Scholten; Natasja F C Visser; Robert H H van den Heuvel; Albert J R Heck
Journal:  J Am Soc Mass Spectrom       Date:  2006-05-19       Impact factor: 3.109

2.  Exploring DNA-binding proteins with in vivo chemical cross-linking and mass spectrometry.

Authors:  Haibo Qin; Yinsheng Wang
Journal:  J Proteome Res       Date:  2009-04       Impact factor: 4.466

3.  Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards.

Authors:  Rachel L Loeber; Erin D Michaelson-Richie; Simona G Codreanu; Daniel C Liebler; Colin R Campbell; Natalia Y Tretyakova
Journal:  Chem Res Toxicol       Date:  2009-06       Impact factor: 3.739

4.  Splicosomal and serine and arginine-rich splicing factors as targets for TGF-β.

Authors:  Oskar Hallgren; Johan Malmström; Lars Malmström; Annika Andersson-Sjöland; Marie Wildt; Ellen Tufvesson; Peter Juhasz; György Marko-Varga; Gunilla Westergren-Thorsson
Journal:  Fibrogenesis Tissue Repair       Date:  2012-04-28

5.  Understanding drug uptake and binding within targeted disease micro-environments in patients: a new tool for translational medicine.

Authors:  György Marko-Varga; Akos Végvári; Melinda Rezeli; Kaiu Prikk; Peeter Ross; Magnus Dahlbäck; Goutham Edula; Ruth Sepper; Thomas E Fehniger
Journal:  Clin Transl Med       Date:  2012-05-31

6.  2DDB - a bioinformatics solution for analysis of quantitative proteomics data.

Authors:  Lars Malmström; György Marko-Varga; Gunilla Westergren-Thorsson; Thomas Laurell; Johan Malmström
Journal:  BMC Bioinformatics       Date:  2006-03-20       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.